The tumor suppressor NPRL2 in hepatocellular carcinoma plays an important role in progression and can be served as an independent prognostic factor

Journal of Surgical Oncology

Volumn 100, Issue 5, 2009, Pages 358-363

  Otani, Satoshi ^a,b   Takeda, Shin ^a   Yamada, Suguru ^a   Sakakima, Yoshikazu ^a   Sugimoto, Hiroyuki ^a   Nomoto, Shuji ^a   Kasuya, Hideki ^a   Kanazumi, Naohito ^a   Nagasaka, Tetsurou ^a   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

Hepatocellular carcinoma; Nitrogen permease regulator like 2 gene; Prognostic factor; Quantitative RT PCR

Indexed keywords

DECARBOXYPROTHROMBIN; MESSENGER RNA; NITROGEN PERMEASE REGULATOR LIKE 2 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER TISSUE; CLINICAL EVALUATION; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

EID: 70349260217     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21241     Document Type: Article

References (19)

1. Arii S, Okamoto E, Imamura M: Registries in Japan: Current status of hepatocellular carcinoma in Japan. Liver Cancer Study Group of Japan. Semin Surg Oncol 1996;12:204-211.
2. Mise K, Tashiro S, Yogita S, et al.: Assessment of the biological malignancy of hepatocellular carcinoma: Relationship to clinicopathological factors and prognosis. Clin Cancer Res 1998;14: 1475-1482. (Pubitemid 28265231)
3. Lerman MI, Minna JD: The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000;60:6116-6133.
4. Wistuba II, Behrens C, Virmani AK, et al.: High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000;60:1949-1960. (Pubitemid 30207657)
5. Zabarovsky ER, Lerman MI, Minna JD: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 2002;21:6915-6935. (Pubitemid 35221938)
6. Li J, Wang F, Haraldson K, et al.: Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C. Cancer Res 2004;64:6438-6443. (Pubitemid 39297898)
7. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer, 4th edition. Tokyo:Kanehara; 2000.
8. Ichida F, Tsuji T, Omata M, et al.: New Inuyama classification: New criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 1996;6:112-119. (Pubitemid 27059904)
9. Ji L, Minna JD, Roth JA: 3p21.3 tumor suppressor cluster prospects for translational applications. Future Oncol 2005;1: 79-92.
10. Burbee DG, Forgacs E, Z€ochbauer-M€uller S, et al.: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93: 691-699. (Pubitemid 32492810)
11. Uno F, Sasaki J, Nishizaki M, et al.: Myristoylation of the FUS1 protein is required for tumor suppression inhuman lung cancer cells. Cancer Res 2004;64:2969-2976. (Pubitemid 38581390)
12. Ueda K, Kawashima H, Ohtani S, et al.: The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res 2006;66:9682-9690. (Pubitemid 44623668)
13. Ando E, Tanaka M, Yamashita F, et al.: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases. Cancer 2002;95: 588-595. (Pubitemid 34810185)
14. Park JY, Ahn SH, Yoon YJ, et al.: Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007;110:129-137. (Pubitemid 46986425)
15. Lau H, Fan ST, Ng IO, et al.: Long term prognosis after hepatectomy for hepatocellular carcinoma: A survival analysis of 204 consecutive patients. Cancer 1998;83:2302-2311. (Pubitemid 28533499)
16. Suehiro T, Sugimachi K, Matsumata T, et al.: Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 1994;73:2464-2471.
17. Koike Y, Shiratori Y, Sato S, et al.: Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: A prospective analysis of 227 patients. Cancer 2001;91:561-569. (Pubitemid 32105702)
18. Shimada M, Yamashita Y, Hamatsu T, et al.: The role of des-gammacarboxy prothrombin levels in hepatocellular carcinoma and liver tissues. Cancer Lett 2000;159:87-94. (Pubitemid 30676218)
19. Tang W, Kokudo N, Sugawara Y, et al.: Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: Association with survival of patients with resectable hepatocellular carcinoma. Oncol Rep 2005;13:25-30.